Securities Star data center news, Shengda biological trading closed, closing price 16.92 yuan. The stock rose by the daily limit at 10:25, but did not open the limit. The closing capital was 38.7706 million yuan, accounting for 1.34% of its current market value.
In terms of capital flow data, the net inflow of main funds on the same day was 25.4953 million yuan, the net inflow of hot capital was 27.2923 million yuan, and the net outflow of retail funds was 15.7212 million yuan. The flow of funds in the past five days is shown in the following table:
The unit is a hot stock of feed and vitamin concepts, with feed concepts up 2.96% and vitamin concepts up 1.74% on the same day.
The investment logic of the stock is as follows:
1. The leader of biotin in the world, with the largest production and sales volume in the world, with a market share of about 30%. Vitamin products include vitamin H (biotin) and vitamin B9 (folic acid), with a capacity of 160t / a for biotin and 500t / a for folic acid. Tongliao Shengda, a holding subsidiary, has a production capacity of 1000 tons / year of vitamin B2; its 19-year biotin income is 255 million yuan and folic acid income is 54 million yuan, accounting for 59.5%. The technical renovation project of the production line of vitamin D3 (coating) with an annual output of 1000 tons is under construction.
2. Biotin and biological antistaling agent leader, the products are widely used in feed addition industry, with FAMI-QS European feed additive and premixed feed quality system certification, France Andisu, China Animal Husbandry shares, Haida Group and other well-known domestic listed enterprises are the company's main partners.
From the perspective of financial situation, Shengda Biological 2021 reported that the company's main income was 390 million yuan, down 13.39% from the same period last year; the net profit from its mother was 47.8898 million yuan, down 68.37% from the same period last year; the non-net profit was 32.6084 million yuan, down 78.14% from the same period last year; and the debt ratio was 26.82%. Investment income 11.653 million yuan, financial expenses 5.0682 million yuan, gross profit margin 28.88%.
The Securities Star valuation analysis tool shows that the good company has a rating of 2.5 stars, a good price rating of 2.5 stars, and a comprehensive valuation rating of 2.5 stars.
Disclaimer: the relevant content according to the public big data analysis, does not constitute investment advice, the stock market is risky, investment should be cautious.